Zentalis
PublicZentalis is now publicly traded
The data on this page reflects Zentalis's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Went Public
Apr 2, 2020
Last Round
Follow-on Offering
Jun 15, 2023
Total Funding Raised
$1.19B
Company Overview
Zentalis Pharmaceuticals (NAS: ZNTL) is a biopharmaceutical company focused on discovering and developing small molecule therapeutics that target key biological pathways in cancer.
Sector
Healthcare
AI Layer
Non-AI
Keywords
azenosertib (WEE1 inhibitor)small molecule cancer therapeuticsWEE1 inhibitor for solid tumorsplatinum-resistant ovarian cancer therapybiomarker-driven oncology drug developmenttargeted oncology drug pipelinecell cycle kinase inhibitororal SERD for breast cancerBCL-2 inhibitor for hematologic malignanciesEGFR inhibitor for non-small cell lung cancerpharmaceutical licensing and collaboration modelclinical-stage oncology company
Zentalis Comparables
Compare Zentalis with similar companies based on industry and business-model similarity.
Zentalis Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Follow-on Offering | Jun 15, 2023 | ||||
| Follow-on Offering | May 18, 2022 | ||||
| Private Placement | Apr 27, 2022 | ||||
| Follow-on Offering | Jul 1, 2021 | ||||
| Follow-on Offering | May 21, 2020 | ||||
IPO | Apr 2, 2020 |
Zentalis Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Matrix | Series C |
| Redmile Group | Series C |
| Jefferies | Follow-on Offering, IPO |
| Surveyor Capital | Series C |
| Farallon Capital Management | Series C |
| Perceptive Advisors | Series A, Series B, Series C |
| Guggenheim Securities | Follow-on Offering, IPO |
Zentalis Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Firmographic Details
HeadquartersNew York City, New York
Employee Range123
Year Founded2014
Last FundingJun 15, 2023